Posted by Michael Wonder on 25 Oct 2021
Merck and Ridgeback announce initiation of a rolling review by the European Medicines Agency for molnupiravir, an investigational oral anti-viral medicine, for the treatment of COVID-19 in adults
25 October 2021 - If granted marketing authorisation by the European Commission, molnupiravir could be the first oral anti-viral medicine for the treatment of COVID-19 in the European Union.
Merck and Ridgeback Biotherapeutics today announced that the EMA has initiated a rolling review for molnupiravir, an investigational oral anti-viral medicine, for the treatment of COVID-19 in adults.
